IDarunavir CAS 206361-99-1 Anti-HIV Purity ≥99.0% API High Purity HIV Protease Inhibitor
Ubonelelo lwabavelisiIimveliso eziNxulumene neDarunavir:
Darunavir CAS 206361-99-1
I-Darunavir Ethanolate CAS 635728-49-3
(2S,3S)-1,2-Epoxy-3-(Boc-Amino)-4-Phenylbutane CAS 98737-29-2
(2R,3S)-1,2-Epoxy-3-(Boc-Amino)-4-Phenylbutane CAS 98760-08-8
(3S)-3-(tert-Butoxycarbonyl)amino-1-Chloro-4-Phenyl-2-Butanone CAS 102123-74-0
| Igama leMchiza | Darunavir |
| Izithethantonye | I-TMC114;UIC-94017 |
| Inombolo yeCAS | 206361-99-1 |
| Inombolo yeCAT | RF-API68 |
| Ubume beStokhwe | Kwi-Stock, iMveliso yeMveliso ukuya kumakhulu eeKilogram |
| Ifomula yeemolekyuli | I-C27H37N3O7S |
| Ubunzima beMolekyuli | 547.66 |
| Uphawu | Ruifu Chemical |
| Into | Iinkcukacha |
| Imbonakalo | Umgubo weCrystalline oMhlophe okanye oMhlophe |
| Ukuchongwa | MS/HNMR HPLC |
| Ukunyibilika | Inyibilika kwi-DMSO, iNyibilika kancinane emanzini |
| Indawo yokunyibilika | 74.0 ~ 76.0℃ |
| Ukuchongwa | 1H NMR |
| Ubunyulu / Indlela yokuHlalutya | ≥99.0% (HPLC) |
| Izinto ezinxulumeneyo | |
| Ukungahlambuluki Okukodwa okuphezulu | ≤0.30% |
| Ukungcola ngokupheleleyo | ≤1.0% |
| Izinyibilikisi ezishiyekileyo | I-Ethanol ≤0.30% |
| Ilahleko ekomisweni | ≤0.50% |
| Intsalela kwi-Ignition | ≤0.10% |
| Iintsimbi ezinzima | ≤20ppm |
| Arsenic | ≤1.5ppm |
| Umgangatho woVavanyo | Umgangatho woShishino |
| Ukusetyenziswa | IDarunavir (CAS 206361-99-1) HIV-1 Protease Inhibitor Anti-HIV |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, Igubu lekhadibhodi, 25kg/Igubu, okanye ngokwemfuno yomthengi.
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ekukhanyeni, ukufuma kunye nokuhlaselwa zizinambuzane.
I-Darunavir (igama lohlobo lwe-Prezista, eyayifudula isaziwa njenge-TMC114) liyeza le-protease inhibitor elisetyenziselwa ukunyanga usulelo lwe-HIV.I-Darunavir lukhetho lonyango olucetyiswayo lwe-OARAC kubantu abadala abanamava ngonyango kunye nolutsha olufikisayo.I-Darunavir luhlobo olutsha lwe non peptide anti retroviral protease inhibitors kunyango lwe-AIDS.Yenziwa okokuqala lisebe le-Johnson pharmaceutical Iceland, iTibotec.Yeyona bioavailability iphezulu kwii-6 protease inhibitors (saquinavir, ritonavirvir, indinavir, naphthalene nelfinavir, amprenavir kunye ne-ABT378/r).Isebenza ngokuthintela ukwakheka kwamasuntswana entsholongwane amatsha nasele ekhulile kumphezulu weeseli ezisulelekileyo kwaye inqanda iprotease yentsholongwane.Xa imveliso isetyenziswa ixesha elide, ngesiqhelo inokwehlisa intsholongwane yentsholongwane kagawulayo egazini, inyuse isibalo seeseli ze-CD4, inciphise ithuba lokosulelwa yi-HIV, iphucule umgangatho wobomi kwaye yandise ubomi.Ibafanele abantu abadala abosulelwe yintsholongwane kagawulayo kodwa abanayo impembelelo kusetyenziso lwamachiza asele ekhona ee-antiretroviral.Ichiza kufuneka lidityaniswe nokusetyenziswa kweedosi eziphantsi ze-ritonavir okanye ezinye ii-antiretroviral agents, ukuze kuphuculwe ukusebenza kakuhle.Umsebenzi we-antiviral kwi-vitro unokuvavanywa ngokuba ngokuchasene ne-lymphocyte eyosulelekileyo kunye ne-lymphocytes egazini le-peripheral.
